Investment Analysts’ Recent Ratings Updates for Hims & Hers Health (HIMS)

A number of firms have modified their ratings and price targets on shares of Hims & Hers Health (NYSE: HIMS) recently:

• 5/26/2026 – Hims & Hers Health had its price target lowered by Bank of America Corporation from $28.00 to $25.00. They now have a “neutral” rating on the stock.
• 5/22/2026 – Hims & Hers Health was given a new $23.00 price target by UBS Group AG.
• 5/22/2026 – Hims & Hers Health had its price target raised by Truist Financial Corporation from $18.00 to $23.00. They now have a “hold” rating on the stock.
• 5/19/2026 – Hims & Hers Health had its price target lowered by Bank of America Corporation from $30.00 to $28.00. They now have a “neutral” rating on the stock.
• 5/13/2026 – Hims & Hers Health had its price target lowered by Bank of America Corporation from $32.00 to $30.00. They now have a “neutral” rating on the stock.
• 5/12/2026 – Hims & Hers Health was downgraded by Weiss Ratings from “hold (c)” to “sell (d)”.
• 5/12/2026 – Hims & Hers Health was given a new $24.50 price target by Jefferies Financial Group Inc..
• 5/12/2026 – Hims & Hers Health was given a new $35.00 price target by UBS Group AG.
• 5/12/2026 – Hims & Hers Health was given a new $32.00 price target by Canaccord Genuity Group Inc..
• 5/12/2026 – Hims & Hers Health had its price target raised by Citigroup Inc. from $24.00 to $28.00. They now have a “neutral” rating on the stock.
• 5/12/2026 – Hims & Hers Health had its price target lowered by JPMorgan Chase & Co. from $35.00 to $33.00. They now have an “overweight” rating on the stock.
• 5/12/2026 – Hims & Hers Health had its price target raised by Needham & Company LLC from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 5/12/2026 – Hims & Hers Health had its “neutral” rating reaffirmed by BTIG Research.
• 5/9/2026 – Hims & Hers Health was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/5/2026 – Hims & Hers Health had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $25.00 price target on the stock.
• 4/24/2026 – Hims & Hers Health is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $35.00 price target on the stock.
• 4/24/2026 – Hims & Hers Health had its price target raised by Bank of America Corporation from $30.00 to $32.00. They now have a “neutral” rating on the stock.
• 4/16/2026 – Hims & Hers Health had its price target raised by Bank of America Corporation from $21.00 to $25.00. They now have a “neutral” rating on the stock.
• 4/11/2026 – Hims & Hers Health was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, Director David B. Wells bought 48,400 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average cost of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. This represents a 27.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 7,950 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $23.64, for a total value of $187,938.00. Following the sale, the chief financial officer owned 262,954 shares in the company, valued at approximately $6,216,232.56. The trade was a 2.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 212,807 shares of company stock valued at $5,473,644. 11.76% of the stock is currently owned by corporate insiders.

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.